As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
Content to be used in accordance with local CPO guidelines
COMBI-EU: Adverse Event Management of Adjuvant Dabrafenib Plus Trametinib (D+T) in Patients with BRAF V600-Mutant Melanoma
Peter Mohr*, Dirk Debus, Imke von Wasielewski, Thomas Tüting, Christoffer Gebhardt, Markus V. Heppt, Jessica C. Hassel, Fabian Ziller, Michael Weichenthal, Manar Aoun, Gaston Schley, Jens Ulrich, Jochen Utikal, Friedegund Meier, Patrick Andres Maximilian Terheyden, Ralf Gutzmer, Dirk Schadendorf
Presentation #1099P – Poster
Hall 6 | Saturday, September 14, 2024 | 09:00-17:00 CEST
Phase 1 study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma
Paolo Ascierto*; Jordi Rodon; Filip de Vos; Valentina Gambardella; Maria de Miguel; Ivan Marquez-Rodas; Marta Gil-Martin; Caroline Robert; Michele Del Vecchio; Victor Moreno; Dirk Schadendorf; Rahima Jamal; Sarah Sloan; Margaret Mclaughlin; Sam Murray; Belen Gomez-Carrillo Ruiz; Emily Hsiue; Susan Moody; Ana Arance
Presentation #1081MO – Mini Oral
Hall 6 | Oviedo Auditorium - Hall 3 | Sunday, September 15, 2024| 15:55 - 16:00 (Mini Oral Presentation) | 16:05 - 16:20 CEST (Discussion)
